Genomic Medicine and Endocrine Autoimmunity as Key to Mitochondrial Disease

Research output: Contribution to specialist publicationEditorialpeer-review

14 Downloads (Pure)


Genomic medicine treatment of diabetics is critical in the
current global diabetes epidemic to prevent the expected diabetes
pandemic predicted to occur by the year 2035. The major concern
with Type 3 diabetes in the global population is related to a
defective SCN with relevance to uncontrolled peripheral glucose
levels and endocrine autoimmune disease. Appetite regulation
and genomic medicine are critical to Sirt 1’s regulation of the MHC
genes with relevance to maintenance of immune recognition and
endocrine hormone treatment of mitophagy. In the developing
world the major concern for a diabetes pandemic is mitophagy and
will require diets with Sirt 1 activators to prevent Type 3 diabetes,
endocrine autoimmunity and mitochondrial disease.
Original languageEnglish
Number of pages3
Specialist publicationGlobal Journal of Endocrinological Metabolism
Publication statusPublished - 5 May 2018


Dive into the research topics of 'Genomic Medicine and Endocrine Autoimmunity as Key to Mitochondrial Disease'. Together they form a unique fingerprint.

Cite this